8-KOther Events

BIOGEN INC. 8-K Report (Feb 19, 2004)

Filed February 19, 2004For Securities:BIIB

Summary

Biogen Inc. (BIIB), in conjunction with Elan Corporation, plc, announced on February 18, 2004, their intention to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ANTEGREN® (natalizumab) as a treatment for multiple sclerosis (MS). This regulatory filing is anticipated to occur in mid-2004, marking a significant step in the development of this potential therapy for MS patients. This announcement is crucial for investors as it signals progress in Biogen's pipeline and potential future revenue streams. The development of ANTEGREN® represents a key strategic initiative for the company, and successful FDA approval would position Biogen to compete in the large and growing market for multiple sclerosis treatments. Investors should monitor the FDA submission timeline and any subsequent communications regarding the review process.

Key Highlights

  • 1Biogen and Elan intend to submit an application to the FDA for ANTEGREN® (natalizumab) approval.
  • 2The intended indication for ANTEGREN® is as a treatment for multiple sclerosis (MS).
  • 3The regulatory submission to the FDA is planned for mid-year 2004.
  • 4This filing is in the form of an 8-K, incorporating a joint press release dated February 18, 2004, as an exhibit.
  • 5The announcement highlights progress in Biogen's drug development pipeline for a significant unmet medical need.

Frequently Asked Questions

ANTEGREN® is the brand name for natalizumab, a drug being developed by Biogen and Elan. Its intended use, as announced, is for the treatment of multiple sclerosis (MS).

Biogen and Elan announced their intention to submit the application for ANTEGREN® to the U.S. Food and Drug Administration (FDA) in mid-year 2004.

This announcement is significant as it indicates a key milestone in the development of a potential new drug for a major disease. Successful FDA approval of ANTEGREN® could lead to new revenue for Biogen and strengthen its position in the biotechnology market, particularly in the area of neurological disorders.

No, as of February 18, 2004, ANTEGREN® was not approved. Biogen and Elan were announcing their *intention* to submit an application for approval to the FDA.